Descending serotonergic inhibitory pathway

The descending serotonergic inhibitory pathway is a major endogenous system for pain control, originating in the periaqueductal gray (PAG) and the rostral ventromedial medulla (RVM) of the brainstem (StatPearls, 2023). These neurons project to the dorsal horn of the spinal cord, where they release serotonin (5-HT) to modulate the transmission of nociceptive information (Dogrul et al., 2012). Acetaminophen (paracetamol) utilizes this pathway as a primary mechanism for its analgesic action; it is metabolized in the brain to N-arachidonoylphenolamine (AM404), which triggers the activation of these descending fibers via TRPV1 and cannabinoid CB1 receptors (Mallet et al., 2008). The resulting spinal serotonin release interacts with specific receptors, such as 5-HT1A and 5-HT3, to produce antinociception (Pickering et al., 2006). Understanding this pathway is vital for pain management, as its dysfunction is linked to chronic pain states and its activity can be influenced by various pharmacological agents, including antidepressants and certain opioids (PubMed, PMID: 18817571). This pathway represents a functional network rather than a single molecular target, integrating multiple receptor systems to regulate sensory input.

Other names

Descending pain modulatory systemDescending inhibitory serotonergic systemSpinal serotonergic inhibitory pathway

Acetaminophen is metabolized to AM404, which enhances endocannabinoid signaling and activates TRPV1 receptors in the brainstem, leading to the activation of descending serotonergic neurons that release serotonin in the spinal cord to inhibit nociceptive transmission via 5-HT receptors (Mallet et al., 2008; Pickering et al., 2006).